Alanine aminotransferase flare-up in hepatitis C virus carriers with persistently normal alanine aminotransferase levels in a hyperendemic area of Japan

Journal of Gastroenterology

Volumn 42, Issue 8, 2007, Pages 673-680

  Uto, Hirofumi ^a   Kurogi, Joji ^b   Takahama, Yuka ^c   Kusumoto, Kazunori ^b   Hayashi, Katsuhiro ^b   Ido, Akio ^d   Kohara, Michinori ^e   Stuver, Sherri O ^f,g   Moriuchi, Akihiro ^a   Hasegawa, Susumu ^a   Oketani, Makoto ^a   Tsubouchi, Hirohito ^a,d  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c Miyazaki Prefectural Industrial Support Foundation   (Japan)

^d KYOTO UNIVERSITY HOSPITAL   (Japan)

^e TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^f BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^g HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

ALT flare up; Community based population; Ferritin; Hepatitis C virus; Persistent normal ALT

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTIC ACID; FERRITIN; HFE PROTEIN; HISTIDINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; ENDEMIC DISEASE; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HETEROZYGOSITY; HUMAN; INCIDENCE; JAPAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; VIRUS CARRIER;

AGED; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; DNA; ENDEMIC DISEASES; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INCIDENCE; JAPAN; MALE; MEMBRANE PROTEINS; MUTATION; PROGNOSIS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL;

EID: 34548008624     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-007-2078-0     Document Type: Article

References (44)

1. MJ Alter D Kruszon-Moran OV Nainan GM McQuillan F Gao LA Moyer 1999 The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engl J Med 341 556-62 10451460 10.1056/ NEJM199908193410802 1:STN:280:DyaK1Mzmt1Whsw%3D%3D
2. JB Wong GM McQuillan JG McHutchison T Poynard 2000 Estimating future hepatitis C morbidity, mortality, and costs in the United States Am J Public Health 90 1562-9 11029989 1:STN:280:DC%2BD3cvnvFWnuw%3D%3D
3. H Rodriguez-Luna DD Douglas 2004 Natural history of hepatitis C following liver transplantation Curr Opin Infect Dis 17 363-71 15241083 10.1097/01.qco.0000136934.06039.01
4. K Tarao Y Rino S Ohkawa O Endo K Miyakawa S Tamai 2004 Sustained low alanine aminotransferase levels can predict the survival for 10 years without hepatocellular carcinoma development in patients with hepatitis C virus-associated liver cirrhosis of Child stage A Intervirology 47 65-71 15192269 10.1159/000077828 1:CAS:528:DC%2BD2cXksl2gu78%3D
5. M de Torres T Poynard 2003 Risk factors for liver fibrosis progression in patients with chronic hepatitis C Ann Hepatol 2 5-11 15094700
6. H Tanaka H Tsukuma H Yamano A Oshima H Shibata 2004 Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus Int J Cancer 112 1075-80 15386355 10.1002/ijc.20507 1:CAS:528:DC%2BD2cXhtVSnsLfL
7. SD Ryder WL Irving DA Jones KR Neal JC Underwood Trent Hepatitis C Study Group 2004 Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study Gut 53 451-5 14960533 10.1136/ gut.2003.021691 1:STN:280:DC%2BD2c%2Fnt1Whug%3D%3D
8. S Ohkoshi H Tawaraya K Kuwana T Harada M Watanabe S Higuchi 1995 A retrospective study of hepatitis C virus carriers in a local endemic town in Japan. A possible presence of asymptomatic carrier Dig Dis Sci 40 465-71 7851213 10.1007/BF02065436 1:STN:280:ByqC2MvhtFY%3D
9. L Pagliaro V Peri C Linea C Camma M Giunta S Magrin 1999 Natural history of chronic hepatitis C Ital J Gastroenterol Hepatol 31 28-44 10091101 1:STN:280:DyaK1M7ptFajsw%3D%3D
10. M Martinot-Peignoux N Boyer D Cazals-Hatem BN Pham A Gervais VL Breton 2001 Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA Hepatology 34 1000-5 11679971 10.1053/jhep.2001.28458 1:STN:280:DC%2BD3MrntF2ktA%3D%3D
11. P Marcellin S Levy S Erlinger 1997 Therapy of hepatitis C: Patients with normal aminotransferase levels Hepatology 26 Suppl 1 133-6S 10.1002/ hep.510260723
12. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C. Hepatology 1997;26 Suppl 1:2-10S
13. P Mathurin J Moussalli JF Cadranel V Thibault F Charlotte P Dumouchel 1998 Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity Hepatology 27 868-72 9500720 10.1002/hep.510270333 1:CAS:528:DyaK1cXhslGhsL4%3D
14. CK Hui T Belaye K Montegrande TL Wright 2003 A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase J Hepatol 38 511-7 12663245 10.1016/S0168-8278(03)00004-7 1:CAS:528:DC%2BD3sXit12jsro%3D
15. ML Shiffman CA Stewart CM Hofmann MJ Contos VA Luketic RK Sterling 2000 Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: Comparison of hepatic histology and response to interferon therapy J Infect Dis 182 1595-601 11069229 10.1086/317612 1:STN:280:DC%2BD3M%2FnvF2mug%3D%3D
16. C Puoti R Castellacci F Montagnese S Zaltron G Stornaiuolo N Bergami 2002 Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: The Italian prospective study of the asymptomatic C carriers (ISACC) J Hepatol 37 117-23 12076870 10.1016/S0168-8278(02)00101-0 1:CAS:528:DC%2BD38XksFylsrc%3D
17. K Tsuji K Yamashita M Yamanishi M Kawakami S Shirahama 2001 Risk of alanine aminotransferase flare-up among asymptomatic hepatitis C virus RNA carriers: A 10 year follow-up study J Gastroenterol Hepatol 16 536-40 11350550 10.1046/j.1440-1746.2001.02474.x 1:STN:280:DC%2BD3M3lt1KhsQ%3D%3D
18. S Zeuzem M Diago E Gane KR Reddy P Pockros D Prati PEGASYS Study NR16071 Investigator Group 2004 Peginterferon alpha-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels Gastroenterology 127 1724-32 15578510 10.1053/ j.gastro.2004.09.050 1:CAS:528:DC%2BD2MXit1Gjtg%3D%3D
19. S Mamori F Suzuki T Hosaka N Akuta T Someya M Kobayashi 2004 Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment J Gastroenterol 39 776-82 15338372 10.1007/s00535-003-1388-0 1:CAS:528:DC%2BD2cXntVaqur8%3D
20. R Suruki K Hayashi K Kusumoto H Uto A Ido H Tsubouchi 2006 Alanine aminotransferase level as a predictor of hepatitis C virus-associated hepatocellular carcinoma incidence in a community-based population in Japan Int J Cancer 119 192-5 16432841 10.1002/ijc.21796 1:CAS:528:DC%2BD28Xkslyjurs%3D
21. Y Tanaka F Kurbanov S Mano E Orito V Vargas JI Esteban 2006 Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality Gastroenterology 130 703-14 16530512 10.1053/j.gastro.2006.01.032 1:CAS:528:DC%2BD28XjsVylsbs%3D
22. H Uto K Hayashi K Kusumoto S Hasuike K Nagata M Kodama 2006 Spontaneous elimination of hepatitis C virus RNA in subjects with persistent infection in a hyperendemic area of Japan Hepatol Res 34 28-34 16360338 10.1016/j.hepres.2005.10.004 1:CAS:528:DC%2BD28XjvVKisQ%3D%3D
23. T Tanaka JYN Lau M Mizokami E Orito E Tanaka K Kiyosawa 1995 Simple fluorescent EIA for detection and quantification of hepatitis C viremia J Hepatol 23 742-5 8750176 10.1016/0168-8278(95)80043-3 1:STN:280:BymA2czhtlE%3D
24. K Hayashi S Hasuike K Kusumoto A Ido H Uto N Kenji 2005 Usefulness of a new immuno-radiometric assay to detect hepatitis C core antigen in a community-based population J Viral Hepat 12 106-10 15655057 10.1111/ j.1365-2893.2005.00558.x 1:STN:280:DC%2BD2M%2FivVKqtg%3D%3D
25. AO Shakil C Conry-Catelina HJ Alter P Hayashi DE Kleiner V Tedeschi 1995 Volunteer blood donors with antibodies to hepatitis C virus: Clinical, biochemical, virologic and histologic features Ann Intern Med 123 330-7 7542854 1:STN:280:ByqA2M7ls1M%3D
26. A Piton T Poynard F Imbert-Bismut L Khalil J Delattre E Pelissier 1998 Factors associated with serum alanine transaminase activity in healthy subjects: Consequences for the definition of normal value, for selection of blood donors and patients with chronic hepatitis C Hepatology 27 1213-9 9581673 10.1002/hep.510270505 1:CAS:528:DyaK1cXjtVSjsbk%3D
27. RG Gish 1999 Standards of treatment in chronic hepatitis C Semin Liver Dis 19 Suppl 1 35-47 10349691 1:CAS:528:DyaK1MXjsFensb0%3D
28. EASL International 1999 Consensus Conference on Hepatitis C Paris, 26-28 February 1999: Consensus Statement J Hepatol 30 956-61 10.1016/ S0168-8278(99)80154-8
29. A Alberti 2005 Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanine aminotransferase levels J Hepatol 42 266-74 15664254 10.1016/ j.jhep.2004.12.004
30. T Okanoue A Makiyama M Nakayama Y Sumida H Mitsuyoshi T Nakajima 2005 A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase J Hepatol 43 599-605 16024129 10.1016/ j.jhep.2005.04.008
31. G Vendemiale I Grattagliano P Portincasa G Serviddio G Palasciamo E Altomare 2001 Oxidative stress in symptom-free HCV carriers: Relation with ALT flare-up Eur J Clin Invest 31 54-63 11168439 10.1046/ j.1365-2362.2001.00747.x 1:CAS:528:DC%2BD3MXhsFWls7w%3D
32. C Rigamonti S Andorno E Maduli S Morelli S Pittau G Nicosia 2002 Iron, hepatic stellate cells and fibrosis in chronic hepatitis C Eur J Clin Invest 32 Suppl 1 28-35 11886429 10.1046/j.1365-2362.2002.0320s1028.x
33. BY Tung MJ Emond MP Bronner SD Raaka SJ Cotler KV Kowdley 2003 Hepatitis C, iron status, and disease severity: Relationship with HFE mutations Gastroenterology 124 318-26 12557137 10.1053/gast.2003.50046 1:CAS:528:DC%2BD3sXhsFOhtbs%3D
34. O Riggio F Montagnese P Fiore S Forino S Giambartolomei C Gandin 1997 Iron overload in patients with chronic viral hepatitis: How common is it? Am J Gastroenterol 92 1298-301 9260793 1:STN:280:ByiH3crnsV0%3D
35. MA Metwally CO Zein NN Zein 2004 Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection Am J Gastroenterol 99 286-91 15046219 10.1111/ j.1572-0241.2004.04049.x 1:CAS:528:DC%2BD2cXitleisLY%3D
36. BR Bacon RS Britton 1989 Hepatic injury in chronic iron overload: Role of lipid peroxidation Chem Biol Interact 70 183-226 2663196 10.1016/ 0009-2797(89)90045-8 1:CAS:528:DyaL1MXkvFWktL0%3D
37. T Furutani K Hino M Okuda T Gondo S Nishina A Kitase 2006 Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein Gastroenterology 130 2087-98 16762631 10.1053/j.gastro.2006.02.060 1:CAS:528:DC%2BD28XntVWit78%3D
38. C Eisenbach SG Gehrke W Stremmel 2004 Iron, the HFE gene, and hepatitis C Clin Liver Dis 8 775-85 15464655 10.1016/j.cld.2004.06.006 vii-viii
39. HA Jackson K Carter C Darke MG Guttridge D Ravine RD Hutton 2001 HEF mutations, iron deficiency and overload in 10500 blood donors Br J Haematol 114 474-84 11529872 10.1046/j.1365-2141.2001.02949.x
40. TV Inglesby R Rai J Astemborski L Gruskin KE Nelson D Vlahov DL Thomas 1999 A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use Hepatology 29 590-6 9918940 10.1002/hep.510290219 1:STN:280:DyaK1M7hvFChtA%3D%3D
41. SC Gordon JWS Fang A Silverman JG McHutchinson JK Albrecht 2000 The significant of the baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C Hepatology 32 400-4 10915749 10.1053/ jhep.2000.9321 1:CAS:528:DC%2BD3cXlvVyjtLg%3D
42. M Naito N Hayashi H Hagiwara N Hiramatsu A Kasahara H Fusamoto 1994 Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels Hepatology 19 871-5 8138259 1:STN:280:ByuC1cnhs1A%3D
43. LA Adinolfi R Utili A Andreana F Tripodi M Marracino M Gambardella 2001 Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C Dig Dis Sci 46 1677-83 11508667 10.1023/A:1010697319589 1:STN:280:DC%2BD3MvmsVahsg%3D%3D
44. M Shiffman M Diago A Tran P Pockros R Reindollar D Drati 2006 Chronic hepatitis C in patients with persistently normal alanine transaminase levels Clin Gastroenterol Hepatol 4 645-52 16630770 10.1016/ j.cgh.2006.02.002 1:CAS:528:DC%2BD28XlsVeqs7c%3D